Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters

Gaurav Garg; Kuruswamy Thurai Prasad; Navneet Singh; Parul Gupta; Valliappan Muthu; Ashim Das; Amanjit Bal

doi:10.4132/jptm.2021.08.08

추천

검색

자료유형: 학술저널

저자정보: Gaurav Garg (Postgraduate Institute of Medical Education and Research) Kuruswamy Thurai Prasad (Postgraduate Institute of Medical Education and Research) Navneet Singh (Postgraduate Institute of Medical Education and Research) Parul Gupta (Postgraduate Institute of Medical Education and Research) Valliappan Muthu (Postgraduate Institute of Medical Education and Research) Ashim Das (Postgraduate Institute of Medical Education and Research) Amanjit Bal (Postgraduate Institute of Medical Education and Research)

저널정보: 대한병리학회 Journal of Pathology and Translational Medicine Journal of Pathology and Translational Medicine 제55권 제6호

발행연도: 2021.11

수록면: 398 - 405 (8page)

DOI: 10.4132/jptm.2021.08.08

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Data on the prevalence of programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in non?small cell lung cancer (NSCLC) and their clinical significance in Indian patients are limited. Methods: Newly diagnosed NSCLC cases (adenocarcinoma or squamous cell carcinoma [SqCC] histology) were included in the present study. The TILs were evaluated based on morphology on hematoxylin and eosin?stained slides. PD-L1 expression in tumors was assessed using immunohistochemistry with rabbit monoclonal antibody (SP263) on the Ventana automated immunostainer. Tumors with PD-L1 expression > 50% on tumor cells were considered PD-L1?positive. Tumors in which TILs occupy > 25% of stroma were considered to have high TILs. The association of PD-L1 expression and TILs with various clinical parameters including overall survival (OS) was investigated. Results: The present study included 128 cases of NSCLC (67 adenocarcinoma, 61 SqCC). PD-L1 positivity was observed in 17.2% of the patients with NSCLC. Baseline characteristics of PD-L1?positive subjects were similar to PD-L1?negative subjects except for a higher prevalence of liver metastasis (18.2% vs. 2.8%; p = .018) and a higher probability of diagnosis from extrapulmonary biopsies. High TILs were observed in 26.6% of the subjects. However, PD-L1 expression and high TIL did not affect OS. Conclusions: PD-L1 positivity and high TILs were observed in 20% and 25% of the patients with NSCLC, respectively, however, neither were predictors of survival in SqCC.

#Lung neoplasms #Non-small cell lung carcinoma #PD-L1 #Immunotherapy #Tumor-infiltrating lymphocytes

참고문헌 (30)

참고문헌 신청

Mok TSK / 2019 / Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial / Lancet 393:1819~1830

Socinski MA / 2018 / Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC / N Engl J Med 378:2288~2301

Gandhi L / 2018 / Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer / N Engl J Med 378:2078~2092

Paz-Ares L / 2018 / Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer / N Engl J Med 379:2040~2051

Zhang M / 2017 / PD-L1 expression in lung cancer and its correlation with driver mutations : a meta-analysis / Sci Rep 7:10255

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!